0 717

Cited 28 times in

A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome

 Eun Ran Kim  ;  Jeong Su Park  ;  Jin Hee Kim  ;  Ji Young Oh  ;  In Jeong Oh  ;  Da Hyun Choi  ;  Yu Seol Lee  ;  I Seul Park  ;  SeungWon Kim  ;  Da Hyun Lee  ;  Jae Hee Cheon  ;  Jin-Woo Bae  ;  Minyoung Lee  ;  Jin Won Cho  ;  In Bok An  ;  Eun Joo Nam  ;  Sang-In Yang  ;  Myung-Shik Lee  ;  Soo Han Bae  ;  Yong-Ho Lee 
 HEPATOLOGY, Vol.75(6) : 1523-1538, 2022-06 
Journal Title
Issue Date
Animals ; Body Weight ; Diet, High-Fat / adverse effects ; Glucagon-Like Peptide 1 / metabolism ; Glucagon-Like Peptide-2 Receptor / metabolism ; Inflammation / metabolism ; Liver / pathology ; Liver Cirrhosis / complications ; Mice ; Mice, Inbred C57BL ; Microbiota* ; Non-alcoholic Fatty Liver Disease* / pathology
Background and aims: Currently there is no Food and Drug Administration-approved drug to treat NAFLD and NASH, the rates of which are increasing worldwide. Although NAFLD/NASH are highly complex and heterogeneous conditions, most pharmacotherapy pipelines focus on a single mechanistic target. Considering the importance of the gut-liver axis in their pathogenesis, we investigated the therapeutic effect of a long-acting dual agonist of glucagon-like peptide (GLP)-1 and GLP-2 receptors in mice with NAFLD/NASH.

Approach and results: C57BL/6J mice were fed a choline-deficient high-fat diet/high fructose and sucrose solution. After 16 weeks, mice were randomly allocated to receive vehicle, GLP1-Fc, GLP2-Fc, or GLP1/2-Fc fusion (GLP1/2-Fc) subcutaneously every 2 days for 4 weeks. Body weight was monitored, insulin/glucose tolerance tests were performed, feces were collected, and microbiome profiles were analyzed. Immobilized cell systems were used to evaluate direct peptide effect. Immunohistochemistry, quantitative PCR, immunoblot analysis, tunnel assay, and biochemical assays were performed to assess drug effects on inflammation, hepatic fibrosis, cell death, and intestinal structures. The mice had well-developed NASH phenotypes. GLP1/2-Fc reduced body weight, glucose levels, hepatic triglyceride levels, and cellular apoptosis. It improved liver fibrosis, insulin sensitivity, and intestinal tight junctions, and increased microvillus height, crypt depth, and goblet cells of intestine compared with a vehicle group. Similar effects of GLP1/2-Fc were found in in vitro cell systems. GLP1/2-Fc also changed microbiome profiles. We applied fecal microbiota transplantation (FMT) gain further insight into the mechanism of GLP1/2-Fc-mediated protection. We confirmed that FMT exerted an additive effect on GLP1-Fc group, including the body weight change, liver weight, hepatic fat accumulation, inflammation, and hepatic fibrosis.

Conclusions: A long-acting dual agonist of GLP-1 and GLP-2 receptors is a promising therapeutic strategy to treat NAFLD/NASH.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jeong Su(박정수) ORCID logo https://orcid.org/0000-0003-4551-4294
Bae, Soo Han(배수한) ORCID logo https://orcid.org/0000-0002-8007-2906
Lee, Da Hyun(이다현) ORCID logo https://orcid.org/0000-0002-5412-6878
Lee, Myung Shik(이명식) ORCID logo https://orcid.org/0000-0003-3292-1720
Lee, Minyoung(이민영) ORCID logo https://orcid.org/0000-0002-9333-7512
Lee, Yong Ho(이용호) ORCID logo https://orcid.org/0000-0002-6219-4942
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.